Healthy
Conditions
Brief summary
An open-label, randomized, three-period, three-way crossover trial of single doses of IX-01 in 12 healthy male subjects. In each period, subjects will receive a single oral dose of 1600 mg IX-01, either as an aqueous dispersion in a fasted state, or as caplets in the fed or fasted state
Detailed description
This is a Relative Bioavailability Study to compare single oral doses of 1600mg IX-01, either as an aqueous dispersion in a fasted state, or as caplets in the fed or fasted state. Each volunteer in the study will receive each of the formulations listed below. Each formulation will be separated by at least a 5-day drug-free (washout) period. * Treatment A: A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fasted conditions * Treatment B: A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fed conditions * Treatment C: A single 1600 mg aqueous dispersion (20 mL) oral dose of IX-01 under fasted conditions. In the fasted treatment periods, dosing will follow an overnight fast of at least 10 hours. In the fed treatment period, following an overnight fast of at least 10 hours, a standard high-calorie, high-fat breakfast meal will be given 30 minutes prior to administration of the study drug. There will be a final follow-up visit 7-10 days after the final dose of study medication.
Interventions
DRUGIX-01 caplets 1600 mg (4 x 400 mg), fasted
oral dose under fasted conditions
DRUGIX-01 caplets 1600 mg (4 x 400 mg), fed
oral dose under fed conditions
DRUGIX-01 aqueous dispersion 1600 mg (20 mL), fasted
oral dose under fasted conditions
Sponsors
Ixchelsis Limited
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Body mass index between 18 and 30 kg/m2 * Body weight of ˃60 kg (132 lbs) at screening * Able to understand the nature of the trial and any hazards of participating. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of the entire trial * Willing to comply with the contraception requirements of the trial * Willing to give written consent to participate * Willing and able to remain in the study unit for the entire duration of each confinement period and return for outpatient visits * Willing and able to consume the entire high-calorie, high-fat breakfast meal in the designated timeframe required during fed study period * Vital signs at both screening and at baseline within: heart rate: 50-90 beats per minute; systolic blood pressure: 100-130 mmHg; diastolic: 60-90 mmHg
Exclusion criteria
* Clinically relevant abnormal history, physical findings, ECG, or laboratory values at screening that could interfere with the objectives of the trial or safety of the volunteer, including any of the following: * Lipid and/or liver function test results \>1.25 times upper limit of normal or another clinical laboratory result judged clinically significant * An international normalised ratio of \>1.2 or a platelet count \<150 x10\^3/mL * History of unexplained syncope * Family history of unexplained sudden death or sudden death due to long QT syndrome * QTcF interval \>450 msec at screening * Bundle branch block or another conduction abnormality during an ECG, other than mild first degree atrio-ventricular block, judged clinically significant * Irregular rhythms during an ECG, other than sinus arrhythmia or occasional supraventricular ectopic beats, judged clinically significant * T-wave configuration of insufficient quality for determination of QT interval, as assessed by ECG and judged clinically significant by the Investigator * Presence of acute or chronic illness or history of chronic illness sufficient to invalidate participation in the trial or make study participation unnecessarily hazardous * Impaired gastrointestinal, endocrine, thyroid, hepatic, cardiovascular, respiratory, hematological, renal or neurological function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness * Surgery (e.g. stomach bypass) or medical condition that might affect absorption, metabolism, or elimination of medicines * Presence or history of severe adverse reaction to any drug and/or a history of skin reactions (rashes) to any drug * Previous allergic response which involved hives, swelling, shortness of breath, or anaphylaxis * Has used any over-the-counter medications, nutritional or dietary supplements, herbal preparations, or vitamins, except short courses of medication (such as acetaminophen), that could interfere with subject safety or the integrity of the trial data within 7 days prior to the first dose of medication * Any prescription medication within 14 days prior to the first dose of study medication * Participation in another clinical trial within 60 days prior to the first dose of study medication * Previous participation in this trial or any other clinical trial of an oxytocin receptor antagonist * Presence or history of drug or alcohol abuse, or intake of more than 21 units of alcohol weekly or more than 5 cigarettes daily * Unwilling or unable to comply with all protocol requirements * Positive urine screen for drugs of abuse * Positive for hepatitis B surface antigen, hepatitis C antibody or Human Immunodeficiency Virus at screening or previously treated for hepatitis B, hepatitis C, or Human Immunodeficiency Virus infection * Donated blood or plasma within 30 days prior to the first dose of study medication * Employee of the investigator site or any company involved in sponsoring, organizing, or conducting the trial, or immediate family of the employee
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of the Area Under the Curve [AUC] in fed versus fasted states | pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose | To determine the effect of a high-fat meal on the pharmacokinetic profile of the IX-01 caplet formulation |
| Pharmacokinetic parameter peak plasma concentration of IX-01 (C max) | pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose | Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state |
| Pharmacokinetic parameter time of peak plasma concentration of IX-01 (t max) | pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose | Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state |
| Pharmacokinetic parameter terminal half-life (t 1/2) | pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose | Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state |
| Pharmacokinetic parameter elimination rate constant (K el) | pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose | Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state |
| Relative bioavailability of the caplet formulation of IX-01 compared with the aqueous dispersion formulation (fasted) | pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose | Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state |
| Pharmacokinetic parameter area under the concentration-time curve (AUC 0-inf) | pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose | Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state |
| area under the concentration-time curve from 0 up to the time of last quantifiable concentration (AUC last) | pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose | Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state |
| The relative bioavailability of IX-01, as judged by AUC 0-inf (F rel) | pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose | Relative bioavailability of the caplet formulation of IX-01 compared with the aqueous dispersion formulation when administered in the fasted state |
| Comparison of Maximum Plasma Concentration [Cmax] in fed versus fasted states | pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose | To determine the effect of a high-fat meal on the pharmacokinetic profile of the IX-01 caplet formulation |
| Comparison of Area Under the Curve [AUC] in fed versus fasted states | pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose | To determine the effect of a high-fat meal on the pharmacokinetic profile of the IX-01 caplet formulation |
| Comparison of Time to Maximum Plasma Concentration [Tmax] in fed versus fasted states | pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose | To determine the effect of a high-fat meal on the pharmacokinetic profile of the IX-01 caplet formulation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety monitoring - adverse events, laboratory data, ECGs, vital signs | Day 0 to Day 21 | To monitor the safety and tolerability of IX-01 |
Countries
United States
Outcome results
None listed